ResMed General Counsel Sells Shares Under Pre-Set Trading Plan
ResMed Global General Counsel Michael J. Rider reported selling shares under a Rule 10b5-1 plan adopted in 2025. He retained direct ownership of more than twelve thousand shares after the transaction.
Closing price · 2026-10-27: $35.50 · -0.95%